Deutschland
- Deutsch
España
- Español
Italia
- ItalianoBreakthrough Cancer Pain
Chronic background pain is common among patients with cancer1 and as part of optimal multimodal approaches to management, may require opioid therapy.
Optimal management of chronic background pain for some cancer patients may require at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.2,3
While having adequate control of chronic background pain, patients may commonly experience breakthrough pain,4 described as transient exacerbations of pain, despite relatively stable and adequately controlled background pain.5
Chronic background pain is common among patients with cancer1 and as part of optimal multimodal approaches to management, may require opioid therapy.
Optimal management of chronic background pain for some cancer patients may require at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.2,3
While having adequate control of chronic background pain, patients may commonly experience breakthrough pain,4 described as transient exacerbations of pain, despite relatively stable and adequately controlled background pain.5
BREAKTHROUGH CANCER PAIN
Provided by
KKI NewCo (known as Grünenthal Meds)
Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.6
Click here for prescribing and adverse event reporting information.
Click here for risk materials.
BREAKTHROUGH CANCER PAIN
Provided by
KKI NewCo (known as Grünenthal Meds)
PecFent® is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.7
Click here for prescribing and adverse event reporting information.
Click here for risk materials.
-
References
1. Portenoy RK, et al. Prim Care & Cancer. 1991;April:27-33.
2. Portenoy RK, et al. J Opioid Manag. 2010;6(5):319-328.
3. Portenoy RK, et al. Pain. 2010;151(3):617-624.
4. Gonella S, et al. Integrative Cancer Therapies. 2019;18.
5. Davies AN, et al. BMJ Support Palliat Care. 2018;8(3):241-249.
6. Abstral® Summary of Product Characteristics.
7. PecFent® Summary of Product Characteristics.
M-GRM-HQ-11-24-0007 June 2025